deferasirox has been researched along with Breast Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakr, AF; El-Sherbiny, IM; Kabil, MF; Mahmoud, MY; Zaafar, D | 1 |
1 other study(ies) available for deferasirox and Breast Neoplasms
| Article | Year |
|---|---|
Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: Enhanced in-vitro and in-vivo cytotoxicity.
Topics: Animals; Breast Neoplasms; Deferasirox; Female; Humans; Lipids; Mice; Nanocapsules; Neoplasm Recurrence, Local; Polyethylene Glycols; Spiro Compounds | 2022 |